In epicardial adipose tissue, expression of the anti-inflammatory adiponectin, in turn, is decreased in cardiovascular disease patients with hypertension[19], suffering from coronary artery disease[4], and in those displaying a combination of features of the metabolic syndrome[20]. Here, ADIPOQ is linked to metabolic syndrome.